Drug ID:Drug161
Drug Name:BMS-986166
CID:118877516
DrugBank ID:DB19053
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NCT03038711
Molecular Formula:C25H33NO2
Molecular Weight:379.5 g/mol
Isomeric SMILES:COC1=CC=CC=C1CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]4CC[C@@](C4)(CO)N
Synonyms:Udifitimod; BMS-986166; Udifitimod [USAN]; UNII-283FTA936D; 283FTA936D; [(1R,3S)-1-amino-3-[(6S)-6-[2-(2-methoxyphenyl)ethyl]-5,6,7,8-tetrahydronaphthalen-2-yl]cyclopentyl]methanol; Udifitimod (USAN); BMS986166; ((1R,3S)-1-amino-3-((S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol; compound 14a [PMID: 30785748]
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt1223 118877516 Bms-986166 1901 S1PR1 Homo sapiens (human) 30785748 Partial agonist

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT03038711 A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy Volunteers PHASE1 COMPLETED Bristol-Myers Squibb Ulcerative Colitis DRUG: BMS-986166|OTHER: Placebo matching BMS-9861… Details
NCT05707429 Sexual Function and Quality of Life Among Patients Suffering From Inflammatory Bowel Disease(Inactive Stage) NULL COMPLETED Assiut University Sexual Function Disturbances|Inflammatory Bowel D… OTHER: The Arabic version of The International In… Details
NCT05687474 Baby Detect : Genomic Newborn Screening NULL COMPLETED Centre Hospitalier Universitaire de Liege Congenital Adrenal Hyperplasia|Familial Hyperinsu… None Details
NCT05570006 Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis PHASE2 COMPLETED AbbVie Ulcerative Colitis DRUG: ABBV-668 Details
NCT05536440 A Study to Learn About Study Medicine Called PF-07261271 in Healthy People PHASE1 COMPLETED Pfizer Healthy DRUG: PF-07261271|DRUG: Placebo Details
NCT05535946 ABTECT - Maintenance PHASE3 ACTIVE_NOT_RECRUITING Abivax S.A. Ulcerative Colitis DRUG: ABX464|DRUG: Placebo Details
NCT05507216 ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 PHASE3 COMPLETED Abivax S.A. Ulcerative Colitis DRUG: ABX464|DRUG: Placebo Details
NCT05507203 ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 PHASE3 COMPLETED Abivax S.A. Ulcerative Colitis DRUG: ABX464|DRUG: Placebo Details
NCT05471492 Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Crohn's Disease PHASE2 WITHDRAWN Telavant, Inc. Crohn Disease DRUG: Investigational Product|DRUG: Placebo Details
NCT05322057 Efficacy of Cx601 (Darvadstrocel) for the Treatment of Perianal Fistulizing Crohn's Disease NULL COMPLETED Medical University of Vienna Crohn Disease|Fistula Perianal DRUG: Darvadstrocel Details
NCT05177835 Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis PHASE2 ACTIVE_NOT_RECRUITING Abivax S.A. Ulcerative Colitis DRUG: ABX464 Details
NCT05107492 Evaluation of the Pharmacokinetics, Safety and Tolerability of Single Dose of PF-06480605 in Chinese Healthy Participants PHASE1 COMPLETED Pfizer Inflammatory Bowel Disease DRUG: 450mg|DRUG: 150mg|DRUG: Placebo Details
NCT07421011 Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers. PHASE1 RECRUITING Valenta Pharm JSC Irritable Bowel Syndrome|Gallstone Disease|GERD|B… DRUG: Trimedat® Details
NCT05078879 Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency PHASE1 COMPLETED National Institute of Allergy and Infectious Diseases (NIAID) Crohn's Disease|Glycogen Metabolism|Inflammatory … DRUG: Empagliflozin Details
NCT05076175 A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis PHASE2|PHASE3 RECRUITING Bristol-Myers Squibb Colitis, Ulcerative DRUG: Ozanimod Details
NCT04978493 A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease PHASE2 TERMINATED Boehringer Ingelheim Crohn Disease DRUG: BI 706321|DRUG: Ustekinumab|DRUG: Placebo Details
NCT04924114 A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002) PHASE1 COMPLETED Merck Sharp & Dohme LLC Ulcerative Colitis DRUG: MK-6194|DRUG: MK-6194-matching placebo Details
NCT07080034 Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis PHASE2 RECRUITING Biocad Ulcerative Colitis (UC) BIOLOGICAL: anti-TL1A monoclonal antibody, low do… Details
NCT04898348 A Study to Investigate Efficacy and Safety of KBL697 in Patients With Mild to Moderate Active Ulcerative Colitis PHASE2 WITHDRAWN KoBioLabs Ulcerative Colitis DRUG: KBL697|DRUG: Placebo Details
NCT07078994 Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease PHASE2 RECRUITING Biocad Crohn's Disease (CD) BIOLOGICAL: anti-TL1A monoclonal antibody, low do… Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
S02 Immunosuppression Classic immunosuppressive drugs azathioprine; 6-mercaptopurine; methotrexate; ciclosporin-A; tacrolimus Ciclosporin-A and tacrolimus bind to specific intracellular… Details
S06 Anti-fibrosis fibrosis; tissue remodelling GS-5745; STNM01 Tissue remodelling and destruction in patients with IBD is … Details
S07 Blockade of cytokine Cytokine signalling apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab Various T-cell subsets, their differentiation pathways and … Details

No related literature

You can run management commands to establish drug-literature associations